EUIPO trademark

OMJJARA

RegisteredEUIPOWord markClass 5Class 42Class 44

"OMJJARA" is a word mark owned by GlaxoSmithKline LLC, filed at the EUIPO on June 3, 2022. It is registered and covers classes 5, 42 and 44.

View GlaxoSmithKline LLC portfolioGet this data via the API
Official EUIPO record
OMJJARA
Word mark as filed with the EUIPO
Status
Registered
Since October 18, 2022
Filed
June 3, 2022
Registered
October 15, 2022
Expires
June 3, 2032
Application no.
018712489
Registration no.
018712489
Office
EUIPO
European Union Intellectual Property Office
Mark type
Word mark
3 classes
Ownership

Who owns OMJJARA

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

GlaxoSmithKline LLC

857 trademarks in the portfolioView company

Representative

Zivko Mijatovic & Partners

Zivko Mijatovic & Partners

Goods and services

What the mark covers

The products and services OMJJARA is filed for, grouped by Nice class.

  • Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; Medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use

  • Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers; scientific research and development; scientific laboratory services; medical laboratory services; conducting clinical trials for others; conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers; DNA screening and analysis services for scientific research purposes

  • Medical services; medical testing services; DNA screening and analysis services for medical purposes

History

What has happened so far

Steps recorded by the EUIPO, newest first.

  1. Bulletin 2023/130 Section C.1.3
  2. Bulletin 2023/058 Section C.1.1
  3. Bulletin 2023/022 Section C.1.3
  4. Bulletin 2022/199 Section C.1.3
  5. Bulletin 2022/197 Section B.2
  6. Representative - Replacement of representative
  7. Bulletin 2022/126 Section A.1
FAQ

About OMJJARA

Who owns the trademark "OMJJARA"?

The EUIPO trademark "OMJJARA" (application 018712489) is owned by GlaxoSmithKline LLC.

What is the status of "OMJJARA"?

Its status at the EUIPO is: registered.

When was "OMJJARA" registered?

It was registered on October 15, 2022 and is due to expire on June 3, 2032.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull OMJJARA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d44c7-3c29-75ff-9b0f-66219a12cc01
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d44c7-3c29-75ff-9b0f-66219a12cc01",
  "object": "trademark",
  "mark_text": "OMJJARA",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "EM",
  "application_number": "018712489",
  "filing_date": "2022-06-03",
  "nice_classes": [
    5,
    42,
    44
  ],
  "owners": [
    {
      "name": "GlaxoSmithKline LLC",
      "entity_id": "ent_019ebbad-4be6-7544-bafb-06b4c2a2ecb2"
    }
  ]
}